FALCO biosystems and Promega Corporation MSI-IVD Kit Collaboration Obtains Approved Companion Diagnostic Status in Japan

06-Feb-2019 11:58 AM



A MSI-IVD Kit by FALCO biosystems, in collaboration with Promega Corporation microsatellite instability (MSI) chemistry and assay design, has obtained companion diagnostic approval in Japan. The Kit is the first pan-tumor companion diagnostic test in Japan and is intended to identify patients suitable for treatment with the anti-PD-1 antibody â??KEYTRUDA®â? (Pembrolizumab). (Photo: Business Wire)

A MSI-IVD Kit by FALCO biosystems, in collaboration with Promega Corporation microsatellite instability (MSI) chemistry and assay design, has obtained companion diagnostic approval in Japan. The Kit is the first pan-tumor companion diagnostic test in Japan and is intended to identify patients suitable for treatment with the anti-PD-1 antibody “KEYTRUDA®” (Pembrolizumab). (Photo: Business Wire)


MADISON, Wis.--()--Promega Corporation today announced FALCO biosystems of Kyoto, Japan, a core business company of FALCO HOLDINGS, working in collaboration with Promega microsatellite instability (MSI) chemistry and assay design, obtained companion diagnostic approval for FALCO’s MSI-IVD from Japan’s regulatory agency, the Ministry of Health, Labour and Welfare (MHLW).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190205005077/en/
 

The MSI-IVD Kit (FALCO), which detects MSI-High within tumor tissues as a biomarker of DNA repair dysfunction, is the first pan-tumor companion diagnostic test in Japan. Its intended use is to identify patients suitable for treatment with the anti-PD-1 antibody “KEYTRUDA®” (Pembrolizumab).

The FALCO kit detects MSI-High status with DNA isolated only from a patient’s tumor tissue, without corresponding submission of a blood sample, using multiplex PCR fragment analysis with Promega designed five mononucleotide repeat markers, which are less susceptible to genetic polymorphisms. The clinical performance study conducted for the kit confirmed the detection capability of MSI-High in 16 different cancer types for stomach, uterine, breast, pancreas, etc. other than colorectal cancer.

Promega MSI technology uses the same loci that have been validated in labs around the world and is the gold standard in nucleic acid based MSI testing. A 2018 College of American Pathologists survey indicated that 70% of respondents performing nucleic acid based MSI testing were doing so using the Promega MSI 1.2 panel of loci.

Promega Corporation’s latest MSI technology was recently granted innovation designation by the Chinese National Medical Products Administration (NMPA) and the company intends to seek US Food and Drug Administration (FDA) approval for IVD status of its MSI 1.2 platform.

About Promega

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 4,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

Contacts

Penny Patterson
VP, Communications
Promega Corporation
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com


 

Media contact

Newsroom
Businesswire Australia and New Zealand

info@businesswire.com

About us

With thousands of distribution and targeting options that reach 162 countries in 50+ languages and 193 industry trade categories, Business Wire gives you access to the world's most powerful press release network. Built on our patented simultaneous and secure NX network and augmented with partnerships with international and national news agencies, Business Wire is a valued and trusted source for breaking news by reporters, investors and consumers.

More in Business Wire Australia and New Zealand